ArcLight to buy TransMontaigne for $350 mln

By Iris Dorbian — 1 month ago

NGL Energy Partners LP has agreed to sell TransMontaigne GP LLC to ArcLight Capital Partners for $350 million cash. The deal is expected to close by the end of this month. UBS Investment Bank is providing financial advice to NGL on the transaction while BofA Merrill Lynch is doing likewise for ArcLight. Denver-based TLPGP is the general partner of TransMontaigne Partners LP, a terminaling and transportation company.

Continue

Apax Partners to exit Italian auto parts maker Rhiag

By Iris Dorbian — 2 months ago

Apax Partners has agreed to sell Italian auto parts maker Rhiag-Inter Auto Parts Italia S.p.A to LKQ Corp. No financial terms were disclosed for the transaction that’s expected to close early in the second quarter of 2016. BofA Merrill Lynch advised LKQ Corporation on the deal while JP Morgan and UBS advised Apax Partners and Rhiag.

Continue

Apax Partners completes AssuredPartners acquisition

By Iris Dorbian — 4 months ago

GTCR has sold insurance broker AssuredPartners to Apax Partners. No financial terms were disclosed. BofA Merrill Lynch served as lead financial advisor to AssuredPartners and GTCR on the transaction with Barclays and Morgan Stanley & Co. also providing financial advice.

Continue

PE-backed MPS goes public

By Iris Dorbian — 4 months ago

New York City-based Multi Packaging Solutions International Limited, a provider of value-added packaging services, has raised about $215 million for its IPO after pricing its stock at $13 per share. The stock began trading Thursday on the New York Stock Exchange under the ticker symbol “MPSX.” BofA Merrill Lynch and Barclays were the lead underwriters. MPS is backed by The Carlyle Group and Madison Dearborn Partners.

Continue

VC-backed CytomX Therapeutics rolls out IPO

By Iris Dorbian — 4 months ago

South San Francisco-based CytomX Therapeutics, a biopharmaceutical company focused on treating cancer, has debuted its IPO after pricing its over 6.6 million shares at $12 per share. The stock began trading on the NASDAQ under the ticker symbol “CTMX.” BofA Merrill Lynch, Jefferies LLC and Cowen and Company are serving as the lead underwriters. CytomX’s backers included Fidelity Management & Research Company, Casdin Capital, Cormorant Asset Management, Deerfield Management, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company.

Continue

Global Jet Capital to acquire GE Capital’s corporate aircraft portfolio

By Iris Dorbian — 4 months ago

Global Jet Capital, a financing solutions provider for private jets, has agreed to buy GE Capital’s aircraft lease and loan portfolio reportedly valued at about $2.5 million. Deutsche Bank Securities Inc, BofA Merrill Lynch and Citi advised Global Jet Capital on the deal. Global Jet Capital, is backed by GSO Capital Partners, The Carlyle Group and AE Industrial Partners.

Continue

H.I.G. Capital-backed Surgery Partners unveils IPO

By Iris Dorbian — 4 months ago

Surgery Partners, a portfolio company of H.I.G. Capital, has rolled out its IPO after pricing its 14.29 million shares at $19 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “SGRY.” BofA Merrill Lynch, Goldman Sachs and Jefferies LLC are serving as lead underwriters. Surgery Partners is surgical services provider.

Continue

Austin Ventures exits Emerus Holdings: CORRECTED

By Luisa Beltran — 5 months ago

Welsh, Carson, Anderson & Stowe has invested in Emerus Holdings. Financial terms weren’t announced. CORRECTION: Austin Ventures, which invested $30 million in 2011, has sold its remaining stake in Emerus and is completely divested, said Jason Lisovicz, Emerus’ VP of marketing. Welsh Carson now owns a minority of Emerus. The firm acquired a much bigger stake than that held by Austin Ventures. Sellers, in addition to Austin, include six Emerus founders and 23 minor investors, Lisovicz said. Woodlands, Texas-based Emerus is a hospital system that provides inpatient and diagnostic care. BofA Merrill Lynch advised Emerus.

Continue

VC-backed CytomX Therapeutics files for IPO

By Iris Dorbian — 5 months ago

South San Francisco-based CytomX Therapeutics, a biopharmaceutical company focused on treating cancer, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be determined. The company plans on trading the stock on the NASDAQ under the ticker symbol “CTMX.” BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will serve as the lead underwriters. CytomX’s backers include Fidelity Management & Research Company, Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company.

Continue

VC-backed Cortendo files for IPO

By Iris Dorbian — 5 months ago

Cortendo AB, a Swedish biopharmaceutical company focused on orphan endocrine disorders, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Cortendo will trade on the NASDAQ under the ticker symbol “SBBP.” BofA Merrill Lynch and Stifel are serving as the lead underwriters. Cortendo’s backers include Longwood Capital, TVM Capital, Granite Point Capital, RA Capital, New Enterprise Associates, Broadfin Capital and HealthCap.

Continue

KPS-backed ECI completes recap

By Iris Dorbian — 6 months ago

Electrical Components International Inc, a portfolio company of KPS Capital Partners, has closed a recapitalization. The recap was backed by a $50 million upsizing of an ECI term loan. Proceeds of the recap were used to fund a $50 million dividend to company shareholders. BofA Merrill Lynch served as lead arranger for the financing of the transaction. Based in St. Louis, Missouri, ECI is a maker of wire harnesses.

Continue

VC-backed Aimmune Therapeutics goes public

By Iris Dorbian — 6 months ago

Brisbane, California-based Aimmune Therapeutics, a biopharmaceutical company focused on treating peanut allergies, has raised $160 million for its IPO after pricing its 10 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AIMT.” BofA Merrill Lynch, Credit Suisse and Piper Jaffray are serving as the lead underwriters. Aimmune’s backers include Longitude Capital, Foresite Capital and Aisling Capital.

Continue

Blackstone to sell AVINTIV to Berry Plastics for about $2.45 bln

By Iris Dorbian — 6 months ago

Berry Plastics Group Inc has agreed to acquire AVINTIV from The Blackstone Group LP for about $2.45 billion. The deal is expected to be completed by the end of the year. Credit Suisse and Barclays provided financial advice to Berry Plastics on the transaction while Citi and BofA Merrill Lynch did likewise for AVINTIV and Blackstone. Headquartered in Charlotte, North Carolina, AVINTIV is a specialty materials provider used in infection prevention, personal care, and high-performance solutions.

Continue

GTCR to exit AssuredPartners

By Luisa Beltran — 7 months ago

Apax Partners has agreed to buy a majority of AssuredPartners Inc. GTCR is the seller. Assured’s management will have a “significant” equity position, a statement said. Financial terms weren’t announced. BofA Merrill Lynch, RBC Capital Markets and Morgan Stanley Senior Funding Inc. are providing debt funding. Lake Mary, Florida-based AssuredPartners is an independent insurance brokerage.

Continue

Houlihan Lokey files to go public

By Luisa Beltran — 7 months ago

Houlihan Lokey Inc. filed to raise as much as $100 million in an IPO, according to a July 10 SEC filing. The Los Angeles-based investment bank is backed by ORIX USA Corp. Houlihan Lokey did not list how many shares it would sell or their price range. That will come in future filings. Houlihan Lokey does plan to trade on the NYSE under the ticker symbol “HLI.” Bookrunners on the deal include BofA Merrill Lynch and Goldman, Sachs & Co.

Continue